Showing results (31-40 of 77) with videos related to
Sort By:
Pageof 8
Expert Opinion on Investigational Drugs|September 29, 2009
Lurasidone: a new drug in development for schizophreniaJonathan M Meyer, Antony D Loebel, Edward SchweizerExpert Opinion on Drug Metabolism & Toxicology|June 1, 2023
Personalized switching from oral to long-acting injectable second-generation antipsychotics in schizophrenia treatment using pharmacokinetic considerationsGeorgios Schoretsanitis, Jonathan M Meyer, Andreas Conca, et al.Journal of Psychiatric Practice|November 26, 2009
Antipsychotic prescribing practices following withdrawal of concomitant carbamazepineDanielle K Strack, Susan G Leckband, Jonathan M MeyerInternational Clinical Psychopharmacology|December 17, 2004
Valproic acid-associated hyperammonemic encephalopathy: a case report from the psychiatric settingRyan J Kimmel, Scott A Irwin, Jonathan M MeyerPsychiatry (Edgmont (Pa. : Township))|September 1, 2010
Real-world Data on Atypical Antipsychotic Medication Side EffectsElisa Cascade, Amir H Kalali, Sagar Mehra, et al.International Clinical Psychopharmacology|April 13, 2004
Risperidone-induced retrograde ejaculation: case report and review of the literatureCatherine Loh, Susan G Leckband, Jonathan M Meyer, et al.Schizophrenia Research|January 22, 2008
Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectinHua Jin, Jonathan M Meyer, Sunder Mudaliar, et al.International Clinical Psychopharmacology|July 22, 2015
Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophreniaJonathan M Meyer, Yongcai Mao, Andrei Pikalov, et al.The Psychiatric Clinics of North America|November 13, 2016
Psychopharmacology of Persistent Violence and AggressionJonathan M Meyer, Michael A Cummings, George Proctor, et al.International Clinical Psychopharmacology|April 27, 2004
Quetiapine-induced diabetes with metabolic acidosisJonathan M Meyer, Susan G Leckband, Catherine Loh, et al.Pageof 8